Black Diamond Therapeutics, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · Cambridge, MA
BDTX chart
What traders are saying about $BDTX
Latest postsBlack Diamond Therapeutics, Inc. news
- Black Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC
Yahoo Finance ·
- FDA feedback supports a late-stage trial path for a lung cancer drug, with possible earlier approval.
Stock Titan ·
- Black Diamond Therapeutics Stock Price Forecast. Should You Buy BDTX?
StockInvest.us ·
- BDTX Q3'26 Earnings: EPS estimate is (0.09) USD
TradingView ·
- Black Diamond Therapeutics downgraded to Buy on slower phase 3 start for lung cancer drug silevertinib.
Pluang ·
- Black Diamond Therapeutics: Delay In Trial Results Leads To A Downgrade, But It's Still A Buy
Seeking Alpha ·
- Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?
Yahoo Finance ·
- Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
Yahoo Finance ·
- Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Yahoo Finance ·
- Black Diamond Therapeutics Touts Silevertinib Lung Cancer Data, Eyes FDA Path
marketbeat.com ·
- BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
Yahoo Finance ·
- Black Diamond Stock Outlook After Q1 Beat and Cash Runway
Yahoo Finance ·
Black Diamond Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Net income | $22.37B | -$69.68B | -$82.4M | -$91.2M |
| Diluted EPS | $0.39 | $-1.27 | $-1.88 | $-2.52 |
| Total assets (year end) | $143.0M | $122.6M | $158.6M | $156.3M |
| Cash and equivalents (year end) | $21.0M | $36.4M | $56.2M | $34.3M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Black Diamond Therapeutics, Inc.
- Ticker
- BDTX (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Cambridge, MA
- Fiscal year end
- December 31
- SEC CIK
- 1701541
- Former names
- Aset Therapeutics, Inc.
Frequently asked questions
What exchange is Black Diamond Therapeutics, Inc. listed on?
Black Diamond Therapeutics, Inc. trades on the Nasdaq under the ticker symbol BDTX.
What industry is Black Diamond Therapeutics, Inc. in?
Black Diamond Therapeutics, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Black Diamond Therapeutics, Inc. headquartered?
Black Diamond Therapeutics, Inc.'s business address on file with the SEC is in Cambridge, MA.
When does Black Diamond Therapeutics, Inc.'s fiscal year end?
Black Diamond Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Black Diamond Therapeutics, Inc. report?
Black Diamond Therapeutics, Inc. reported $0 in revenue for calendar year 2020, according to its SEC filings.